Compare DOV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOV | ONC |
|---|---|---|
| Founded | 1947 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 33.5B |
| IPO Year | 1994 | N/A |
| Metric | DOV | ONC |
|---|---|---|
| Price | $203.85 | $284.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $223.20 | ★ $386.70 |
| AVG Volume (30 Days) | ★ 1.1M | 233.7K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.94 | N/A |
| Revenue | ★ $6,992,118,000.00 | N/A |
| Revenue This Year | $6.95 | $759.19 |
| Revenue Next Year | $4.40 | $14.51 |
| P/E Ratio | ★ $25.64 | $614.06 |
| Revenue Growth | ★ 2.51 | N/A |
| 52 Week Low | $143.04 | $196.53 |
| 52 Week High | $237.54 | $385.22 |
| Indicator | DOV | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 29.62 |
| Support Level | $197.41 | $234.09 |
| Resistance Level | $210.75 | $284.51 |
| Average True Range (ATR) | 5.03 | 8.91 |
| MACD | -3.16 | -4.35 |
| Stochastic Oscillator | 6.72 | 1.56 |
Founded in 1955 by George Ohrstrom, Dover has become an industrial behemoth through the acquisition of dozens of esteemed brands. The company is organized into five segments through which it designs and manufactures highly engineered components, such as vehicle repair, factory automation, welding, aerospace, fuel dispensing, printing, liquid handling, refrigeration, and can-making equipment. It has operations around the globe but generates over half of its revenue in the United States.
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.